Optimal medical therapy for heart failure: eplerenon in a hospital setting (case report)

Heart failure (HF) is a major issue in the modern society. A growing number of users, re-hospitalizations due to decompensation and disability cause significant economic costs and a high workload for both in-patient and out-patient practitioners. This article highlights the practical importance of timely prescription of mineralocorticoid receptor antagonists (specifically, eplerenone, a selective drug) in inpatient and outpatient settings. The efficacy and tolerability of this drug are established through the results of large studies. Eplerenone is included in the clinical guidelines of the Ministry of Health of Russian Federation, national guidelines on acute heart failure of the Russian Cardiological Society and Russian Therapeutic Society guidelines on HF diagnosis and treatment. It is recommended for all patients with moderate and severe HF, irrespective of the origin and LV ejection fraction. The established safety of eplerenon allows for its use in multimorbid patients. This case report demonstrates the effects of bioequivalent eplerenone (Espiro) for stabilizing the condition after HF decompensation with a transient decrease in LV ejection fraction. KEYWORDS: heart failure, decompensation, mineralocorticoid receptor antagonists, eplerenon. FOR CITATION: Sedykh D.Yu., Kashtalap V.V., Barbarash O.L. Optimal medical therapy for heart failure: eplerenon in a hospital setting (case report). Russian Medical Inquiry. 2022;6(1):45–51 (in Russ.). DOI: 10.32364/2587-6821-2022-6-1-45-51.